Sklice is a U.S. brand name for ivermectin lotion 0.5%, a topical medicine labeled for treatment of head-lice infestation in people 6 months of age and older. It belongs to the human-use scalp-treatment category—not to the oral ivermectin tablet category or the prescription ivermectin cream 1% category used for inflammatory lesions of rosacea. The name Sklice identifies a particular branded product history, while the ingredient, 0.5% concentration, purpose, age directions and Drug Facts warnings establish the type of medicine a shopper is actually examining.
Sklice first received U.S. approval as a prescription head-lice lotion in 2012. In October 2020, the FDA approved a switch to nonprescription, or over-the-counter (OTC), use for the labeled product. That regulatory change means an authentic OTC Sklice product does not require a prescription for its labeled use; it does not establish that every retailer currently stocks the original brand. FDA approval, an existing product label and a live purchase offer are separate facts. Shoppers should check whether a listing is the branded Sklice product or a different ivermectin lotion 0.5% item marketed under a generic or retailer name.
This page focuses on Sklice as a distinct brand: its U.S. regulatory history, Drug Facts identity, label-directed limits, packaging checks and relationship to other lice-lotion products. For a category-wide overview, see ivermectin lotion 0.5%; for the ingredient-level and packaging comparison, see Sklice versus generic ivermectin lotion. Brand availability, seller terms and checkout details must be confirmed for the specific item being offered rather than inferred from historical marketing records.
Sklice is the trade name associated with ivermectin lotion 0.5% for treatment of head lice. The active ingredient is ivermectin at a concentration of 0.5%, which corresponds to 5 mg per gram of lotion. A brand name should always be read alongside the dosage form and concentration: Sklice is a scalp lotion, not an oral tablet, injectable preparation, veterinary product or facial cream. Those categories carry different labeling, indications and access conditions despite sharing an ingredient name.
The Sklice product originally received FDA approval through a new drug application (NDA) in 2012. The FDA later approved the prescription-to-OTC switch in 2020. Its branded label can therefore be discussed as an established U.S. product identity without claiming that the original branded carton is currently available at a particular chain, online seller or geographic location. An FDA approval record establishes the regulatory history of the product; actual marketing activity and inventory require independent confirmation.
A published U.S. Sklice label identifies a human OTC medicine for external use on the scalp, with Drug Facts directions and warnings. Historic labels can also show a specific package size or NDC, but an NDC is a product identifier rather than an inventory report. When reading an offer, compare the brand shown on the exact carton with its ingredient name, strength, labeler and product category. A page that says only “compare to Sklice” may be advertising a generic item instead of the original brand.
| Brand fact | U.S. product context | What the fact does not prove |
|---|---|---|
| Brand name | Sklice (ivermectin lotion) | That every ivermectin lotion listing is the original brand |
| Active ingredient and concentration | Ivermectin 0.5% topical lotion | Interchangeability with 1% facial cream or oral tablets |
| Labeled indication | Treatment of head lice | Approval for scabies, rosacea or other skin conditions |
| Age boundary | Labeled for ages 6 months and older | Permission to use in infants younger than 6 months |
| Initial U.S. approval | Prescription-brand approval in 2012 | That an old prescription carton is the current OTC package |
| OTC transition | FDA approved nonprescription use in 2020 | Current retail stock or a universal selling price |
| Label category | Human OTC Drug Facts labeling | That an unrelated veterinary ivermectin product is suitable |
| Package identifiers | NDC, labeler and net contents on the specific package | That all labelers or sellers offer identical commercial packs |
The 2020 FDA prescription-to-nonprescription decision changed the way the labeled Sklice product could be obtained in the United States. Instead of requiring a prescription for its approved head-lice use, the switched product is intended to be selected and used according to its Drug Facts information. The FDA evaluates whether consumers can understand directions and precautions without routine supervision by a prescriber before allowing this type of switch. This history is central to Sklice as a branded product and is different from the still-prescription status of oral ivermectin tablets and ivermectin cream 1%.
OTC status is not a statement that every person can use the product in every situation. The Drug Facts label limits use to the specified age group and treatment site, identifies situations requiring medical advice and contains warnings about irritation and accidental ingestion. Someone unsure whether live head lice are present, dealing with lice around the eyelashes, or caring for an infant younger than 6 months should not treat an OTC designation as a reason to disregard those restrictions.
A retailer may list Sklice by the brand name, ivermectin by its ingredient name, or a generic package that references the branded active ingredient. These are not necessarily identical offers. Because companies and product listings can change, the safest evergreen distinction is regulatory: the FDA permitted nonprescription Sklice for its labeled use; whether a specific Sklice-branded product is currently being sold is a separate question for the seller and the latest product record. The topical ivermectin overview also explains why this OTC status cannot be applied to other ivermectin formulations.
The U.S. label describes Sklice as a treatment for head-lice infestation in individuals 6 months of age and older. Its intended site of application is scalp hair and scalp skin. Head lice are not the same condition as body lice, pubic lice, scabies or a nonspecific itchy scalp. Identifying the problem before selecting a product matters because an infestation may not be the cause of itching or visible flakes; treating an unrelated condition with head-lice lotion can delay appropriate assessment.
The age warning is precise: the OTC Drug Facts label says not to use the product on children under 6 months of age. It also says that an adult should supervise use for children from 6 months through under 12 years. These are label-specific boundaries, not suggestions to select a different strength or increase the amount applied. The correct interpretation is to use only the indicated product for the indicated population and seek professional advice when the patient falls outside the label.
Sklice is not labeled to treat eyebrow or eyelash lice. Its warnings also prohibit use near the eyes and inside the nose, ears, mouth or vagina. If lice are present around eyelashes or eyebrows, the label instructs the reader to see a doctor rather than apply the scalp lotion to the face. The brand should not be represented as an approved therapy for scabies, Demodex-associated facial conditions, rosacea or acne. Those are distinct topics with different products, evidence and clinical considerations.
Sklice Drug Facts describes a single-use scalp treatment. The labeled process starts with identifying lice and following the package warnings. Hair and scalp are to be dry before application, and the lotion is spread thoroughly over the scalp and hair. The 10-minute contact period begins after the hair and scalp have been completely covered; the label then calls for rinsing with water. These points are presented here to explain the marketed product and why reading the exact instructions matters—not as an individualized treatment regimen.
The OTC directions specify further details, including waiting before shampooing, washing hands after use and discarding the tube after the single application. They also state that nit combing is not required for the labeled product to work, although it may be used to remove dead lice and nits. Not every competing head-lice product has the same timing, shampooing, combing or repeat-treatment instructions. The fact that one Sklice label describes a single use must not be copied onto a different active ingredient or formulation.
Do not treat continuing itching as automatic evidence that more Sklice should be applied. The label advises against repeating treatment of the same infestation without talking to a healthcare provider first; persistent lice or symptoms warrant reassessment. Package directions and safety warnings should be checked on the specific item purchased, since a generic lotion can have its own inactive ingredients and packaging presentation. For a discussion of the broader OTC ingredient category rather than this brand, use the broader ivermectin lotion product guide.
As a topical scalp product, Sklice is for external use only. Avoid exposing the eyes, mucous membranes or unrelated skin sites. Its label lists possible eye redness, soreness or irritation if contact occurs and notes that dry skin, dandruff or a burning sensation of the skin can occur. If the lotion gets into the eyes, the label instructs users to flush gently with water. Breathing difficulty, continuing scalp irritation, rash or other concerning reactions require attention according to the Drug Facts warnings.
The label advises consultation before use in people with relevant skin conditions or sensitivities, in those who are pregnant or planning pregnancy, and in those who are breastfeeding or planning to breastfeed. Avoiding contact with an infant during breastfeeding is particularly relevant to the application site. The inactive-ingredient list can matter for people with known sensitivities; it should be checked on the exact package rather than assumed to be identical across all ivermectin 0.5% lotions.
Like other medicines, Sklice should be kept out of children’s reach, and it must not be swallowed. If accidental ingestion occurs, the product labeling directs immediate medical help or contact with a Poison Control Center. Neither an OTC brand label nor anecdotal purchasing advice substitutes for assessment of unusual symptoms or uncertain diagnoses. The site’s ivermectin safety overview provides broader formulation distinctions, but the Sklice Drug Facts panel remains the governing set of directions for this specific lotion.
The brand name Sklice and the generic name ivermectin lotion describe related but not always identically packaged products. The original Sklice application is an NDA, while an approved generic ivermectin lotion may be associated with an abbreviated new drug application (ANDA). The FDA has approved a generic ivermectin lotion 0.5% referencing Sklice. FDA generic approval is based on the relevant regulatory requirements; it is not evidence that the original brand is consistently on store shelves or that one retailer has both products in stock.
A generic can share the same active ingredient, concentration, dosage form and labeled treatment purpose with the reference product while differing in carton design, labeler, NDC or certain inactive ingredients. It is therefore inaccurate to describe every package as physically identical or to treat brand prominence in a retailer search result as proof of original-brand identity. Some generic packages use comparison wording that mentions Sklice; the legal product identity still depends on the product label itself.
For ingredient-based shoppers, the practical first check is whether the carton states “ivermectin lotion 0.5%” and carries human OTC head-lice Drug Facts directions. For shoppers specifically seeking the Sklice-branded item, it is also necessary to identify the brand on the exact offered carton and confirm that the listing is not simply a generic with the same active ingredient. A deeper side-by-side examination is available in the Sklice vs generic ivermectin lotion comparison; broader shopping-cost factors are addressed separately at ivermectin lotion pricing.
Brand authorization, marketed status and store inventory are three different questions. FDA records confirm the Sklice brand’s NDA history and nonprescription approval; a published DailyMed Sklice label documents a marketed product presentation. Neither record independently verifies that the same labeled package is being shipped to retailers at the moment a shopper searches. Any statement that the original Sklice brand is currently available should therefore be supported by the latest brand marketing information and confirmation from the seller, rather than by the existence of an older label alone.
A historical U.S. Sklice OTC label identifies a single-use lotion package with an NDC and net contents; those are useful examples of how a brand product is identified. An NDC belongs to a particular labeler and package, not to every ivermectin lotion sold in the country. A more recently updated ingredient-name label may have a different NDC or application number while also referring to Sklice as a comparison brand. When evaluating a listing, match the exact product name, strength, active ingredient, package size, Drug Facts directions and labeler to the item the seller claims to provide.
Retail pages can remain online after packaging, distributors or brand arrangements change. Unverified photographs, cached promotions and third-party marketplace search tags should not override the actual carton or a retailer’s current order confirmation. An inability to find a matching original-brand package is not proof that ivermectin lotion 0.5% is unavailable as a category. It means the availability of the specific branded item has not been established. The goal is accurate identification, not a fabricated list of active Sklice stockists.
| Verification point | Check for a Sklice-branded offer | What it tells you |
|---|---|---|
| Exact package name | Does the offered carton itself identify Sklice, or does the listing say only “compare to Sklice”? | Distinguishes brand identity from an ingredient comparison |
| Active ingredient | Does Drug Facts state ivermectin 0.5%? | Confirms the topical head-lice formulation |
| Intended use | Does the label state head-lice treatment for human scalp use? | Avoids mixing products approved for other conditions |
| NDA versus ANDA context | Is the record for original Sklice or for a separately approved generic? | Clarifies regulatory product identity |
| NDC and labeler | Do the package code and company match the presented item? | Helps identify the actual labeled product, not its availability |
| Net contents and package count | What does the physical carton contain? | Prevents comparisons between mismatched retail packs |
| Drug Facts directions | Are age limits, warnings and single-use instructions readable? | Confirms the product has necessary consumer information |
| Seller confirmation | Can the seller confirm the exact item offered before purchase? | Addresses product substitution or out-of-date catalog pages |
| Seal and receipt | Is the package intact and consistent with the confirmed order? | Supports safe receipt and follow-up with the seller |
Because the labeled Sklice product is OTC, a prescription is not a prerequisite for its approved head-lice use. However, OTC does not mean that every online marketplace listing is authentic, that a specific retailer currently carries original Sklice, or that an unrelated ivermectin product is appropriate. A pharmacy or retailer can explain whether an item is the brand, an FDA-approved generic formulation, or a different head-lice treatment. The details of the particular product being sold matter more than search keywords on a store page.
Before paying, verify a U.S. seller’s identity, the full product name, active-ingredient strength, label photographs, net contents, expiration information and final checkout terms. A clear Drug Facts panel and tamper-evident package are more meaningful than unsupported claims of superior results or “limited-stock” urgency. Online offers for veterinary ivermectin, unapproved mixtures or prescription-only rosacea cream are not substitutes for a human OTC head-lice lotion. For general topical product distinctions, compare the 1% cream and 0.5% lotion before ordering.
If a retailer offers a generic instead of the requested brand, verify the label and ingredients rather than assuming every difference is either dangerous or irrelevant. Ask a pharmacist about ingredient sensitivities or the suitability of a product for a particular age group. Purchasing decisions can also involve packaging size, delivery fees or return rules, but this branded overview does not list merchants or promise shipping windows. These questions are appropriately resolved using the seller’s current terms and the actual item offered.
The cost of an OTC Sklice-branded package, when offered, is not the same question as the general price of ivermectin lotion 0.5%. Brand identity, package size, retailer policies and availability of generic alternatives may influence which offers can be compared. A headline price without confirmation of the exact product is not a reliable brand quote. Because dollar amounts, promotions and inventory change, a brand-specific offer should be checked with the seller; the Sklice price guide explains the factors behind branded costs without relying on dated quotes.
An OTC purchase may be paid directly by the customer, but any insurance reimbursement or spending-account eligibility must be verified under the relevant plan or account rules. Coverage should not be inferred merely from a product’s former prescription history. If the brand is unavailable, a pharmacist may be able to identify an appropriate human OTC ivermectin lotion 0.5% product, but no particular generic, seller or inventory outcome should be assumed. The comparison should begin with labeled purpose, concentration and instructions, not with a price tag alone.
Other OTC head-lice treatments may contain different active ingredients and follow different directions or age restrictions. For example, permethrin products and ivermectin lotion should not be treated as matching products solely because both are used against head lice. Readers researching ingredient-level options can use ivermectin lotion versus permethrin. Sklice remains a brand-specific resource for understanding its regulatory history and package identity, while diagnosis, suitability and treatment questions belong with a clinician or pharmacist when the label does not resolve them.
Sklice is a U.S. brand of ivermectin lotion 0.5% intended for topical treatment of head lice. It is a human scalp-use product, not an oral ivermectin tablet or prescription ivermectin cream 1% used for rosacea. The exact OTC package must be identified from its Drug Facts label.
The FDA approved a prescription-to-OTC switch for Sklice lotion 0.5% in 2020. The labeled OTC product does not require a prescription for its approved use. This regulatory status does not guarantee that the original brand is currently stocked by any specific retailer.
No. The OTC label says not to use Sklice on children under 6 months of age. It also calls for adult supervision for children 6 months through under 12 years. Questions about treating very young infants should be directed to a healthcare professional.
No. The U.S. Sklice lotion label is for head-lice infestation on the scalp. Scabies and rosacea are separate conditions, and the presence of ivermectin in other medications does not make Sklice an approved substitute for them.
The products can share the same active ingredient and concentration, but they may differ in branding, NDC, labeler, carton presentation and inactive ingredients. FDA-approved generic status should be verified for the specific product. An advertisement that says “compare to Sklice” is not necessarily selling original Sklice.
No. FDA approval confirms a regulatory status, not live retail inventory. Published drug labels and marketplace pages can remain accessible when commercial supply changes. A seller must confirm the exact Sklice-branded product being offered, and current brand marketing status should be checked before making availability claims.
The Drug Facts directions describe application to dry scalp and hair, followed by a 10-minute period after complete coverage and rinsing with water. The label has additional instructions and warnings that must be read in full on the actual package. Do not transfer these directions to a different head-lice treatment.
The product is labeled for a single use. The Drug Facts label advises against repeating treatment of the same infestation without speaking to a healthcare provider first and recommends reassessment if infestation continues. Continuing symptoms are not a reason to repeat or increase treatment on one’s own.
The OTC Drug Facts directions state that nit combing is not necessary for the labeled product to work, although a fine-tooth comb may be used to remove dead lice and nits. That statement is specific to the product’s labeling and does not apply automatically to other lice medicines.
Not necessarily. Differences depend on the specific brand or generic package, quantity, retailer and checkout conditions. The original Sklice package and a generic product must first be identified correctly; then the seller’s current price can be checked. No nationwide brand price or guaranteed savings can be inferred from the product name.